NCT05303259

Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury in Patients With Head and Neck Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 204 (estimated)
• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.

Detailed description

Radiotherapy-induced brain injury (RI) is a serious complication of radiotherapy in head and neck cancer (HNC) patients. Previous studies have confirmed that Bevacizumab has a good effect on patients with symptomatic RI .However, patients with RI maybe do not show clinical symptoms in the early stage. The clinical symptoms will appear with the progression of the RI lesion. There has been no relevant research on whether early intervention is necessary for asymptomatic RI. The investigators conduct this multicenter, randomized clinical research to explore the efficacy and safety of Bevacizumab in asymptomatic RI.

Conditions

• Brain Injuries

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab 2.5mg/kg, q2w, 4 cycles.

Timeline

• Start date: 2021-11-01
• Primary completion: 2024-12-30
• Completion: 2025-12-30
• First posted: 2022-03-31
• Last updated: 2022-03-31

Locations

1 site across 1 country: China